Myriel

Myriel is a preclinical-stage biotech developing MUR-2425, a brain-penetrant inhibitor of caspase-2 designed to block the formation of the neurotoxic tau fragment Δtau314. Founded on foundational academic research by CEO Dr. Karen Hsiao Ashe, the company has demonstrated rapid reversal of memory loss in mouse models within 30 minutes. Myriel is advancing its lead candidate toward clinical trials with the goal of creating a once-daily treatment for mild to moderate dementia across multiple neurodegenerative indications, including Alzheimer's, Parkinson's, and Huntington's diseases.

Computational drug discovery platform utilizing electrophilic fragment screening for the design of selective small molecule inhibitors, specifically targeting enzyme active sites like caspase-2.

Myriel competes in the crowded neurodegenerative disease space against large pharma and biotech companies targeting amyloid, tau, and other pathways. Its differentiation lies in targeting the specific Δtau314 fragment for rapid symptomatic reversal, a niche not directly addressed by most late-stage candidates, which primarily aim for slower disease modification.